[ad_1]
Modern, like the US company Pfizer, is at the forefront of the fight against potential innovations in coronavirus vaccines. There are rumors that the modern vaccine could be introduced in December of this year. This time the company reported the possible price of the vaccine. It has been argued that the price that was initially set may be lowered later. British news agency Reuters reported.
Adar Punawala, Director of the Serum Institute, has announced that the price of two doses of Oxford vaccine in India will be between Rs. He said the price was being set in such a way that the vaccine could reach the general public. Pfizer has not yet disclosed the potential price of the vaccine. However, the head of the company, Albert Borla, has indicated that the price of Pfizer’s vaccine will be announced in December.
Modern CEO Stephen Bansell said that a dose of Corona Ticker will cost between US $ 25-36, which is equivalent to between 2,100 and 3,100 Bangladeshi rupees.
Bansel added that European countries have submitted proposals to buy modern vaccines. The listed prices are being discussed with the European Commission. They have asked to keep the price of the listed dose below 25.
Modern claims its vaccine is 94 percent effective. According to the results of the final trial of the third episode, more than 30,000 people have been vaccinated in the United States. The volunteers produced doses of ticker antibodies in their bodies. Antibodies appropriate to the vaccine dose are also being produced in the body of people over 50 years of age. In some cases, some older volunteers have been found to have higher levels of antibodies to the virus than younger ones. Which means it’s also going to be the most delusional time of the year. Which is one of the biggest positives of the vaccine trial.
Modern has developed the mRNA vaccine under the supervision of Anthony Fouchi, director of the US National Institute of Allergies and Infectious Diseases and a White House epidemiologist. The study involved scientists from the NIH Center for Vaccine Research. Modern also has a 10-year contract with Lonza Group AG, one of Switzerland’s largest pharmaceutical and vaccine companies.
Executive Director Stephen said that between 2 million and 5 million doses of the vaccine could reach the US market by the end of this year. They plan to bring another 300 million doses next year.
Following the announcement of the success of the vaccine by Moderner, the UK submitted a proposal for 5 million doses. The country’s health minister, Matt Hancock, said 5 million doses had been ordered at an early stage. Previously, the British government had signed an agreement for the Pfizer vaccine. Hancock added that a proposal was submitted for 3.5 million doses of the Pfizer vaccine. Britain will also buy vaccines from six other pharmaceutical companies.
[ad_2]
